Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus.  In this study, ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

O'Day emphasized the upcoming FDA decision for Lenacapavir for PrEP, expected by June 19, 2025, and its potential launch in the U.S. shortly thereafter. This is one of nine HIV product launches ...

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the ...

Why it matters: Gilead's stable outlook amid two key uncertainties—potential pharmaceutical tariffs and the upcoming launch of lenacapavir for the prevention of HIV—was reassuring. Gilead has ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and four million HIV-negative people in the country would need to use the jab ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...